Literature DB >> 1539459

Recombinant P.69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection.

M Roberts1, J P Tite, N F Fairweather, G Dougan, I G Charles.   

Abstract

The immunogenicity of recombinant (r-) pertactin was examined. Parenteral immunization of mice with natural or r-pertactin produced a similar increase in serum anti-pertactin antibodies and a decrease in Bordetella pertussis lung counts following aerosol challenge. Study of the kinetics of B. pertussis growth in the respiratory tract of immunized and control mice revealed that immunization with r-pertactin halted the multiplication of B. pertussis in the lungs and facilitated the early onset of bacterial clearance. In the trachea, bacterial numbers declined sharply in immunized animals during the first 3 days after challenge but thereafter B. pertussis numbers remained fairly constant throughout the rest of the experiment. Very low doses (0.1 micrograms) of r-pertactin were immunogenic and protective but only if the antigen was absorbed to alhydrogel. In vitro proliferation assays with lymphocytes from mice primed with either natural or r-pertactin indicated that the major T-cell epitopes of pertactin are conserved in the recombinant protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1539459     DOI: 10.1016/0264-410x(92)90418-j

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis.

Authors:  J W Petersen; P H Ibsen; K Hasløv; I Heron
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

2.  Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution.

Authors:  F R Mooi; H van Oirschot; K Heuvelman; H G van der Heide; W Gaastra; R J Willems
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

3.  Contribution of Bordetella bronchiseptica filamentous hemagglutinin and pertactin to respiratory disease in swine.

Authors:  Tracy L Nicholson; Susan L Brockmeier; Crystal L Loving
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

4.  Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis.

Authors:  R Strugnell; G Dougan; S Chatfield; I Charles; N Fairweather; J Tite; J L Li; J Beesley; M Roberts
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

5.  Proteomics-identified Bvg-activated autotransporters protect against bordetella pertussis in a mouse model.

Authors:  Daan de Gouw; Daan de Gouw; Marien I de Jonge; Marien I de Jonge; Peter W M Hermans; Hans J C T Wessels; Aldert Zomer; Alinda Berends; Catherine Pratt; Guy A Berbers; Frits R Mooi; Dimitri A Diavatopoulos
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

6.  Outer Membrane Vesicles (OMV)-based and Proteomics-driven Antigen Selection Identifies Novel Factors Contributing to Bordetella pertussis Adhesion to Epithelial Cells.

Authors:  Gianmarco Gasperini; Massimiliano Biagini; Vanessa Arato; Claudia Gianfaldoni; Alessandro Vadi; Nathalie Norais; Giuliano Bensi; Isabel Delany; Mariagrazia Pizza; Beatrice Aricò; Rosanna Leuzzi
Journal:  Mol Cell Proteomics       Date:  2017-12-04       Impact factor: 5.911

7.  Vaccine-Mediated Activation of Human TLR4 Is Affected by Modulation of Culture Conditions during Whole-Cell Pertussis Vaccine Preparation.

Authors:  Marieke E Hoonakker; Lisa M Verhagen; Elder Pupo; Alex de Haan; Bernard Metz; Coenraad F M Hendriksen; Wanda G H Han; Arjen Sloots
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

8.  Safety testing of acellular pertussis vaccines: Use of animals and 3Rs alternatives.

Authors:  Marieke Hoonakker; Juan Arciniega; Coenraad Hendriksen
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.